New therapeutic agents for hypertension

British Journal of Clinical Pharmacology

Volumn 42, Issue 1, 1996, Pages 37-41

  Reid, John L ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

Angiotensin receptor antagonists; Hypertension; Imidazoline receptors

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMIDAZOLINE RECEPTOR; LOSARTAN; METHYLDOPA; MOXONIDINE; NEW DRUG; RILMENIDINE; THIAZIDE DIURETIC AGENT;

CONFERENCE PAPER; COUGHING; DRUG MECHANISM; DRUG RESEARCH; DRUG TOLERABILITY; HUMAN; HYPERTENSION; PRIORITY JOURNAL; SEDATION; XEROSTOMIA;

EID: 0029679860     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.03817.x     Document Type: Conference Paper

References (48)

1. Dollery CT, Harington M, Kaufmann G. The mode of action of chlorothiazide in hypertension. Lancet 1959; i: 1215-1218.
2. Dollery CT, Emslie-Smith D, McMichael J. Bretylium toxylate in the treatment of hypertension. Lancet 1960; i: 296-299.
3. Dollery CT, Emslie-Smith D, Shillingford JP. Haemodynamic effects of guanethidine Lancet 1961; ii: 331-334.
4. Dollery CT, Harington, Hodge JV. Haemodynamic studies with methyldopa: effect on cardiac output and response to pressor amines. Br Heart J 1963; 25: 670-676.
5. Samaan N, Dollery CT, Fraser TR. Diabetogenic action of benzothiadiazines: serum-insulin-like activity in diabetes worsened or precipitated by thiazide diuretics. Lancet 1963; ii: 1244-1247.
6. Welborn TA, Breckenridge A, Rubinstein AH, Dollery CT, Fraser TR. Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet 1966; i: 1336-1337.
7. Paterson JW, Dollery CT. Effect of propranolol in mild hypertension. Lancet 1966; ii: 1148-1150.
8. Beilin LJ, Bulpitt CJ, Coles EC, Dollery CT, Johnson BF, Mearns C, Munro-Faure AD, Turner SC. Computer-based hypertension clinic records: a co-operative study. Br Med J 1974; 2: 212-216.
9. Breckenridge A, Dollery CT, Parry EHO. Prognosis of treated hypertension - changes in life expectancy and causes of death between 1952 and 1967. Quart J Med 1970; 39:411-429.
10. Bulpitt CJ, Dollery CT, Carne S. A symptom questionnaire for hypertensive patients. J Chronic Dis 1974; 27: 309-315.
11. Dollery CT, Davies DS, Draffan GH, et al. Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther 1976; 19: 11-18.
12. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke and coronary heart disease. Part 1. Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
13. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease. Part 2. Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
14. Isles CG, Walker LM, Beevers DG, et al. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertension 1986; 4: 141-156.
15. Bosquet P, Feldman J, Tibirica E, et al. Imidazoline receptors: a new concept in central regulation of arterial pressure. Am J Hypertension 1992; 5: 58S-63S.
16. Ernsberger P, Elliott HL, Weismann HJ, et al. Moxonidine a second generation central antihypertension drug. Cardiovasc Drug Rev 1993; II: 411-431.
17. Central actions of drugs in Mood pressure regulation, ed. Davies DS, Reid JL, Tunbridge Wells: Pitman Medical, 1995.
18. Reid JL, Elliott HL. Methyldopa. In Handbook of hypertension Vol 3, Clinical pharmacology of antihypertensive drugs, ed. Doyle A. Amsterdam, Elsevier, 1988: 103-124.
19. Conolly ME, Briant RH, George CF, Dollery CT. A crossover comparison of clonidine and methyldopa in hypertension. Eur J Clin Pharmacol 1972; 4: 222-227.
20. Wing LMH, Reid JL, Davies DS, Dargie HJ, Dollery CT. Pharmacokinetic and concentration effect relationships of clonidine in essential hypertension. Eur J Clin Pharmacol 1977; 12: 463-469.
21. Reid JL. The clinical pharmacology of clonidine and related central antihypertensive agents. Br J Clin Pharmacol 1981; 12: 295-302.
22. Zamboulis C, Reid JL. Effects of single and multiple doses of guanfacine in essential hypertension. Clin Pharmacol Ther 1980; 28: 707-718.
23. 2 receptors and blood pressure regulation in man: studies with guanfacine and azepexole. Br J Clin Pharmacol 1983; 15: 463S-469S.
24. Hamilton CA. The role of imidazoline receptors in blood pressure regulation. Pharmacol Ther 1992; 54: 231-248.
25. Dollery CT, Davies DS, Duchier J, Pannier B, Safar M. Dose and concentration effect relations for rilmenidine. Am J Cardiol 1988; 61: 60D-66D.
26. Planitz V. Crossover comparison of moxonidine and clonidine in mild to moderate hypertension. Eur J Clin Pharmacol 1984; 27: 147-152.
27. Panfilov V, Morris AD, Donnelly R, Scemama M, Reid JL. The effects of rilmenidine and atenolol on mental stress, dynamic exercise and autonomie function in mild to moderate hypertension. Br J Clin Pharmacol 1995; 40: 563-570.
28. Macphee GJA, Howie CA, Elliott HL, Reid JL. A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects. Br J Clin Pharmacol 1992; 33: 261-267.
29. 1 imidazoline receptor, ed. van Zwieten PA, Hamilton CA, Pritchard BNC, London. Royal Society of Medicine Services, 1994: 1-23.
30. Ernsberger P, Meeley MP, Reis DJ. An endogenous substance with clonidine like properties. Brain Res 1988; 441: 309-318.
31. Bousquet P, Feldman J, Tibirica E, et al. Imidazole receptors and clonidine displacing substance in relationship to control of blood pressure, neuroprotection and adrenomedullary secretion. Am J Hypertension 1992; 5: 51S-57S.
32. The Renin Angiotensin System, ed. Robertson JIS, Nicholls MG, London: Gower Medical, 1993.
33. Streeten DP, Anderson GH. Angiotensin receptor blocking drugs. In Handbook of Hypertension, Vol 5. Clinical pharmacology of antihypertensive drugs, ed AE Doyle, Amsterdam: Elsevier, 1984: 246-271.
34. Wong PC, Price WA, Chin AT, Duncia JV, Carini DJ, Wexler RR. Non peptide angiotensin II antagonists - the pharmacology of EXP3174 an active metabolite of Dup753. J Pharmacol Exp Ther 1990; 255: 211-217.
35. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ. Angiotensin II receptors and angiotensin II receptor antagonists 1993; 45: 205-251.
36. 2 receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95: 651-657.
37. MacFadyen RJ, Reid JL. Angiotensin receptor antagonists as a treatment for hypertension. J Hypertension 1994; 12: 1333-1338.
38. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ. Oral administration of Dup753, a specific angiotensin II antagonist to normal male volunteers. Circulation 1991; 83: 1333-1342.
39. Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM. Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol 1993; 22: 579-584.
40. Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL. Dose ranging study of the angiotensin type I receptor antagonist losartan in salt deplete normal man. J Cardiovasc Pharmacol 1993; 21: 732-738.
41. Doig JK, MacFadyen RJ, Sweet CS, Reid JL. Haemodynamic and renal responses to losartan potassium in salt replate/deplete normal volunteers. J Cardiovasc Pharmacol 1995; 25: 511-517.
42. Goldberg MR, Tanaka W, Barchowsky A, et al Effects of losartan on blood pressure, plasma renin activity and angiotensin II in volunteers. Hypertension 1993; 21: 704-713.
43. Mallion JM, Bradstreet D, Makris L, Goldberg A. Antihypertensive efficacy and tolerability of once daily losartan. J Hypertension 1995; 13: S35-S42.
44. Weber MA, Byyny RL, Pratt H, et al. Blood pressure effects of the angiotensin II receptor blocker losartan. Arch Intern Med 1995; 155: 405-411.
45. Goldberg A, Dunlay M, Sweet C. Safety and tolerability of losartan compared to atenolol, felodipine and angiotensin converting enzyme inhibition. J Hypertension 1995; 13: S77-S80.
46. Lacourciere Y, Brunner HR, Irwin R, Karlberg B, Ramsay LE, Snavely DB. Effects of modulators of the renin angiotensin system on cough. J Hypertension 1994; 12: 1387-1393.
47. Sweet CS, Rucinstea EJ. Losartan in heart failure: preclinical experience and initial clinical outcomes. Eur J Cardiol 1994; 15: 139-144.
48. Husain A. The chymase-angiotensin system in humans. J Hypertension 1993; 11: 1155-1159.